Table 2 Baseline characteristics of the study population
Variables | Baseline characteristics of UC | P | Baseline characteristics of CD | P | ||
|---|---|---|---|---|---|---|
Responders | Non-responders | Responders | Non-responders | |||
(n = 41) | (n = 28) | (n = 47) | (n = 25) | |||
Age (years) | 50.00(32.50–55.50) | 45.50(35.25–55.50) | 0.956 | 25.00(22.00–41.00) | 29.00(20.00–39.00) | 0.696 |
Male, n (%) | 20(48.78%) | 18(64.29%) | 0.228 | 29(61.70%) | 18(72.00%) | 0.444 |
BMI (kg/m2) | 20.58(18.99–24.57) | 19.35(17.41–21.54) | 0.024 | 18.78 ± 2.83 | 18.09 ± 4.37 | 0.477 |
Temperature > 37.8 °C, n (%) | 9(21.95%) | 10(35.71%) | 0.275 | 16(34.04%) | 10(40.00%) | 0.618 |
ESR (mm/h) | 43.98 ± 30.00 | 58.14 ± 30.52 | 0.060 | 48.41 ± 30.62 | 55.05 ± 30.93 | 0.385 |
CRP (mg/L) | 55.00(15.74–85.78) | 55.86(14.65–90.91) | 0.687 | 36.50(13.60–68.60) | 48.60(19.58–74.46) | 0.391 |
Hb (g/L) | 102.98 ± 23.87 | 115.18 ± 26.62 | 0.051 | 105.98 ± 25.94 | 101.84 ± 26.67 | 0.525 |
Alb (g/L) | 33.35 ± 6.49 | 33.40 ± 6.76 | 0.975 | 35.84 ± 6.64 | 30.66 ± 7.37 | 0.003 |
CMV seropositivity, n (%) | 5(12.20%) | 5(17.86) | 0.729 | 0(0.00%) | 0(0.00%) | - |
Disease duration (months) | 18.00(8.50–66.00) | 12.00(1.25–24.00) | 0.069 | 12.00(5.00–36.00) | 16.00(6.50–48.00) | 0.275 |
Disease extent, n (%) | Â | Â | 0.321 | - | ||
Proctitis (E1) | 4(9.76%) | 1(3.57%) | Â | |||
Left-sided colitis (E2) | 14(34.14%) | 6(21.43%) | Â | |||
Extensive colitis (E3) | 23(56.10%) | 21(75.00%) | Â | |||
Disease location, n (%) | - | Â | Â | 0.544 | ||
Ileal (L1) | 9(19.15%) | 3(12.00%) | Â | |||
Colonic (L2) | 13(27.66%) | 5(20.00%) | Â | |||
Ileocolonic (L3) | 25(53.19%) | 17(68.00%) | Â | |||
Disease behavior, n (%) | Â | Â | 0.239 | |||
Inflammatory (B1) | 38(80.85%) | 16(64.00%) | Â | |||
Stricturing (B2) | 6(12.77%) | 7(28.00%) | Â | |||
Penetrating (B3) | 3(6.38%) | 2(8.00%) | Â | |||
Stool frequency (n/day) | 7(6–12) | 9(6–12) | 0.319 | 5(3–7) | 4(2–8) | 0.392 |
Bloody stools, n (%) | 41(100.00%) | 28(100.00%) | - | 20(42.55%) | 8(32.00%) | 0.452 |
Parenteral manifestations, n (%) | 5(12.20%) | 7(25.00%) | 0.205 | 20(42.55%) | 10(40.00%) |  > 0.999 |
Clinical severity (SCCAI/HBI) | 10(9–11) | 11(10–12) | 0.012 | 14(13–17) | 16(16–18) | 0.049 |
Endoscopic severity (UECIS/SES-CD) | 6(6–7) | 6(5–7) | 0.290 | 16(14–20) | 17(16–22) | 0.184 |
Colonic dilatation, n (%) | 4(9.76%) | 7(25.00%) | 0.106 | 2(4.26%) | 2(8.00%) | 0.606 |
SATI (cm2/m2) | 42.29 ± 20.41 | 21.16 ± 9.64 |  < 0.001 | 16.21(9.92–32.65) | 21.23(5.77–34.65) | 0.882 |
VATI (cm2/m2) | 24.43(13.46–41.53) | 14.71(8.56–18.41) | 0.001 | 11.63(6.50–17.89) | 21.33(11.32–33.02) | 0.004 |
PSAI (cm2/m2) | 1.37(0.84–1.61) | 1.15(0.98–1.34) | 0.124 | 0.82(0.53–0.96) | 0.79(0.65–1.05) | 0.590 |
MATI (cm2/m2) | 5.33 ± 1.79 | 4.20 ± 2.32 | 0.025 | 3.44(2.40–4.95) | 3.14(1.69–6.27) | 0.892 |
MFI (cm2/m2) | 0.62(0.52–0.82) | 0.73(0.61–0.82) | 0.136 | 0.61(0.43–0.86) | 1.11(0.88–1.49) |  < 0.001 |